Here is a comprehensive answer on the drug of choice for large/widespread (disseminated) fungal infections:
Drug of Choice for Disseminated/Widespread Fungal Infections
First-Line: Amphotericin B (AmB)
Amphotericin B is the drug of choice for large-spread (disseminated/invasive systemic) fungal infections. It holds the broadest antifungal spectrum of any available agent and has fungicidal (not just fungistatic) activity.
"Amphotericin B remains the antifungal agent with the broadest spectrum of action... Owing to its broad spectrum of activity and fungicidal action, amphotericin B remains a useful agent for nearly all life-threatening mycotic infections."
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
Spectrum of Coverage
AmB is active against virtually all clinically significant fungi:
| Organism | Notes |
|---|
| Candida albicans | Most common systemic yeast |
| Cryptococcus neoformans | Meningitis in immunocompromised |
| Histoplasma capsulatum | Endemic mycosis |
| Blastomyces dermatitidis | Endemic mycosis |
| Coccidioides immitis | Disseminated coccidioidomycosis |
| Aspergillus fumigatus | Invasive mold |
| Mucor / Rhizopus (mucormycosis) | AmB is drug of choice |
Exceptions (intrinsically resistant): Candida lusitaniae, Pseudallescheria boydii, Scedosporium prolificans
Mechanism of Action
Amphotericin B binds ergosterol in the fungal cell membrane - a lipid unique to fungi (not present in mammalian cells). It forms aggregates that sequester ergosterol like a sponge, disrupting membrane integrity and causing fungal cell death. (Goodman & Gilman's, 14th Ed.)
Preferred Formulation: Liposomal AmB (L-AmB / AmBisome)
Four formulations exist:
| Formulation | Notes |
|---|
| C-AMB (conventional, deoxycholate) | Effective but high nephrotoxicity (azotemia in 80%) |
| L-AMB (Liposomal - AmBisome) | Preferred - same efficacy, much less nephrotoxic and infusion-related reactions |
| ABCD (colloidal dispersion) | More infusion reactions than L-AMB |
| ABLC (lipid complex - Abelcet) | Less nephrotoxic than C-AMB |
Dose: 0.5-1 mg/kg/day IV (conventional); 3-5 mg/kg/day (liposomal)
Strategy: Induction + Step-Down
For severe disseminated infections, the standard approach is:
- Induction: Amphotericin B IV - rapidly reduces fungal burden
- Step-down (maintenance): Switch to an azole (e.g., itraconazole, fluconazole, voriconazole) once clinical response achieved
- In immunosuppressed patients, azole maintenance may be lifelong to prevent relapse
This is especially important for:
- Severe cryptococcal meningitis
- Disseminated histoplasmosis
- Disseminated coccidioidomycosis
- Invasive aspergillosis / mucormycosis
Adverse Effects to Monitor
| Effect | Details |
|---|
| Nephrotoxicity | Azotemia in ~80% with C-AMB; dose-dependent; use L-AmB to reduce |
| Infusion reactions | Fever, chills, hypotension, rigors - premedicate with paracetamol, antihistamines, hydrocortisone |
| Hypokalemia/Hypomagnesemia | From renal tubular damage |
| Normochromic normocytic anemia | Due to reduced erythropoietin |
Summary Table: Antifungal Drug Classes
| Class | Examples | Use |
|---|
| Polyenes | Amphotericin B | Disseminated/severe infections - broadest spectrum |
| Azoles | Fluconazole, Voriconazole, Itraconazole, Posaconazole | Maintenance / less severe infections |
| Echinocandins | Caspofungin, Micafungin, Anidulafungin | Invasive candidiasis/aspergillosis; second-line |
| Flucytosine | 5-FC | Combination with AmB for cryptococcal meningitis |
Bottom line: For large-spread/disseminated fungal infection, Liposomal Amphotericin B is the drug of choice due to its broad-spectrum fungicidal activity with reduced toxicity compared to conventional formulations.
- Katzung's Basic and Clinical Pharmacology, 16th Edition
- Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Edition